Dermatomyositis (DM) Clinical Trials and Treatments

Dermatomyositis is a systemic autoimmune disease characterized by inflammation of skin and skeletal muscles, with characteristic immune patterns including antibodies to myositis-associated antigens. The pathophysiology involves antibody-mediated complement activation leading to destruction of muscle and skin vasculature, with prominent CD4+ T cell infiltration. Muscle involvement typically affects proximal muscles (shoulders, hips) more than distal muscles, causing progressive weakness that can be profoundly disabling.

The most common symptoms of Dermatomyositis include Progressive muscle weakness, typically in proximal muscles (shoulders, hips), Distinctive heliotrope rash over eyelids (purple/violet discoloration), Gottron papules on knuckles, elbows, and knees, Photosensitive rashes on chest and shoulders, Dysphagia (difficulty swallowing) from pharyngeal muscle involvement, among others. Approximately 1-10 cases per million people; juvenile-onset incidence about 0.4 cases per 100,000 children. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Dermatomyositis from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. The treatment landscape changed in August 2026, when the FDA approved Lisraya (brepocitinib) for adults with dermatomyositis, the first targeted therapy for the disease. It is a once-daily pill that blocks the TYK2 and JAK1 signaling behind the disease, and in its Phase 3 trial most patients improved while also cutting back or stopping steroids.

Yes. As of September 2026, Trial Friend lists 1 FDA-approved drug used to treat Dermatomyositis: Lisraya (brepocitinib), first approved in 2026.

Each has its own page with what the label covers, side effects and how it is given, and the Treatments section of this page adds any further approved drugs found in FDA labeling data.

The exact cause of Dermatomyositis is not fully understood. It is not caused by a single gene; inherited variants raise risk, and immune, environmental or other triggers are thought to set it off. Autoimmune; HLA associations only shift risk. Diagnosis rests on myositis-specific autoantibodies, muscle enzymes, imaging, and biopsy rather than gene testing. Approximately 1-10 cases per million people; juvenile-onset incidence about 0.4 cases per 100,000 children. Research is ongoing to better understand the disease mechanism.

No single gene test diagnoses Dermatomyositis. The diagnosis rests on clinical findings and laboratory or imaging results; genetic variants shift risk rather than cause the disease. Autoimmune; HLA associations only shift risk. Diagnosis rests on myositis-specific autoantibodies, muscle enzymes, imaging, and biopsy rather than gene testing.

Some trials collect genetic samples for research or check specific risk markers. The Genetic Testing section of this page shows any tests listed in the NIH Genetic Testing Registry, which for this condition are usually research or risk-marker tests rather than diagnostic ones.

Eligibility for Dermatomyositis clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Dermatomyositis clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.